The priority review voucher issued for FDA's first approval of a Chagas disease treatment is expected to help ensure affordable access to the product.
The agency announced Aug. 29 that it granted accelerated approval for benznidazole for use in children age two to 12...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?